335 related articles for article (PubMed ID: 31286496)
21. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30.
Fu Y; Ye D; Chen H; Lu W; Ye F; Xie X
Gynecol Oncol; 2007 Apr; 105(1):66-73. PubMed ID: 17234259
[TBL] [Abstract][Full Text] [Related]
22. Reduced RBX1 expression induces chromosome instability and promotes cellular transformation in high-grade serous ovarian cancer precursor cells.
Bungsy M; Palmer MCL; Jeusset LM; Neudorf NM; Lichtensztejn Z; Nachtigal MW; McManus KJ
Cancer Lett; 2021 Mar; 500():194-207. PubMed ID: 33290867
[TBL] [Abstract][Full Text] [Related]
23. SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth.
Mills KA; Roach ST; Quinn JM; Guo L; Beck HM; Lomonosova E; Ilivicky AR; Starks CM; Lawrence JA; Hagemann AR; McCourt C; Thaker PH; Powell MA; Mutch DG; Fuh KC
Gynecol Oncol; 2018 Nov; 151(2):337-344. PubMed ID: 30190114
[TBL] [Abstract][Full Text] [Related]
24. Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
Lheureux S; N'Diaye M; Blanc-Fournier C; Dugué AE; Clarisse B; Dutoit S; Giffard F; Abeilard E; Briand M; Labiche A; Grellard JM; Crouet H; Martin S; Joly F; Poulain L
Int J Cancer; 2015 Mar; 136(5):E340-50. PubMed ID: 25066666
[TBL] [Abstract][Full Text] [Related]
25. Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.
Pils D; Bachmayr-Heyda A; Auer K; Svoboda M; Auner V; Hager G; Obermayr E; Reiner A; Reinthaller A; Speiser P; Braicu I; Sehouli J; Lambrechts S; Vergote I; Mahner S; Berger A; Cacsire Castillo-Tong D; Zeillinger R
Eur J Cancer; 2014 Jan; 50(1):99-110. PubMed ID: 24176298
[TBL] [Abstract][Full Text] [Related]
26. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
[TBL] [Abstract][Full Text] [Related]
27. Antagonizing the spindle assembly checkpoint silencing enhances paclitaxel and Navitoclax-mediated apoptosis with distinct mechanistic.
Henriques AC; Silva PMA; Sarmento B; Bousbaa H
Sci Rep; 2021 Feb; 11(1):4139. PubMed ID: 33603057
[TBL] [Abstract][Full Text] [Related]
28. Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest.
Russell P; Hennessy BT; Li J; Carey MS; Bast RC; Freeman T; Venkitaraman AR
Oncogene; 2012 May; 31(19):2450-60. PubMed ID: 22056875
[TBL] [Abstract][Full Text] [Related]
29. Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells.
Lee EA; Keutmann MK; Dowling ML; Harris E; Chan G; Kao GD
Mol Cancer Ther; 2004 Jun; 3(6):661-9. PubMed ID: 15210851
[TBL] [Abstract][Full Text] [Related]
30. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
31. PRP4K is a HER2-regulated modifier of taxane sensitivity.
Corkery DP; Le Page C; Meunier L; Provencher D; Mes-Masson AM; Dellaire G
Cell Cycle; 2015; 14(7):1059-69. PubMed ID: 25602630
[TBL] [Abstract][Full Text] [Related]
32. Prostate cancer cell response to paclitaxel is affected by abnormally expressed securin PTTG1.
Castilla C; Flores ML; Medina R; Pérez-Valderrama B; Romero F; Tortolero M; Japón MA; Sáez C
Mol Cancer Ther; 2014 Oct; 13(10):2372-83. PubMed ID: 25122070
[TBL] [Abstract][Full Text] [Related]
33. Deregulation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancer.
Chong T; Sarac A; Yao CQ; Liao L; Lyttle N; Boutros PC; Bartlett JMS; Spears M
J Ovarian Res; 2018 Apr; 11(1):27. PubMed ID: 29618387
[TBL] [Abstract][Full Text] [Related]
34. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
36. BAG3-mediated Mcl-1 stabilization contributes to drug resistance via interaction with USP9X in ovarian cancer.
Habata S; Iwasaki M; Sugio A; Suzuki M; Tamate M; Satohisa S; Tanaka R; Saito T
Int J Oncol; 2016 Jul; 49(1):402-10. PubMed ID: 27120977
[TBL] [Abstract][Full Text] [Related]
37. Phyllanthusmin Derivatives Induce Apoptosis and Reduce Tumor Burden in High-Grade Serous Ovarian Cancer by Late-Stage Autophagy Inhibition.
Young AN; Herrera D; Huntsman AC; Korkmaz MA; Lantvit DD; Mazumder S; Kolli S; Coss CC; King S; Wang H; Swanson SM; Kinghorn AD; Zhang X; Phelps MA; Aldrich LN; Fuchs JR; Burdette JE
Mol Cancer Ther; 2018 Oct; 17(10):2123-2135. PubMed ID: 30018048
[TBL] [Abstract][Full Text] [Related]
38. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.
Kang EY; Weir A; Meagher NS; Farrington K; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Bolithon A; Popovic G; Leung B; Tang K; Lambie N; Millstein J; Alsop J; Anglesio MS; Ataseven B; Barlow E; Beckmann MW; Berger J; Bisinotto C; Bösmüller H; Boros J; Brand AH; Brooks-Wilson A; Brucker SY; Carney ME; Casablanca Y; Cazorla-Jiménez A; Cohen PA; Conrads TP; Cook LS; Coulson P; Courtney-Brooks M; Cramer DW; Crowe P; Cunningham JM; Cybulski C; Darcy KM; El-Bahrawy MA; Elishaev E; Erber R; Farrell R; Fereday S; Fischer A; García MJ; Gayther SA; Gentry-Maharaj A; Gilks CB; ; Grube M; Harnett PR; Harrington SP; Harter P; Hartmann A; Hecht JL; Heikaus S; Hein A; Heitz F; Hendley J; Hernandez BY; Polo SH; Heublein S; Hirasawa A; Høgdall E; Høgdall CK; Horlings HM; Huntsman DG; Huzarski T; Jewell A; Jimenez-Linan M; Jones ME; Kaufmann SH; Kennedy CJ; Khabele D; Kommoss FKF; Kruitwagen RFPM; Lambrechts D; Le ND; Lener M; Lester J; Leung Y; Linder A; Loverix L; Lubiński J; Madan R; Maxwell GL; Modugno F; Neuhausen SL; Olawaiye A; Olbrecht S; Orsulic S; Palacios J; Pearce CL; Pike MC; Quinn CM; Mohan GR; Rodríguez-Antona C; Ruebner M; Ryan A; Salfinger SG; Sasamoto N; Schildkraut JM; Schoemaker MJ; Shah M; Sharma R; Shvetsov YB; Singh N; Sonke GS; Steele L; Stewart CJR; Sundfeldt K; Swerdlow AJ; Talhouk A; Tan A; Taylor SE; Terry KL; Tołoczko A; Traficante N; Van de Vijver KK; van der Aa MA; Van Gorp T; Van Nieuwenhuysen E; van-Wagensveld L; Vergote I; Vierkant RA; Wang C; Wilkens LR; Winham SJ; Wu AH; Benitez J; Berchuck A; Candido Dos Reis FJ; DeFazio A; Fasching PA; Goode EL; Goodman MT; Gronwald J; Karlan BY; Kommoss S; Menon U; Sinn HP; Staebler A; Brenton JD; Bowtell DD; Pharoah PDP; Ramus SJ; Köbel M
Cancer; 2023 Mar; 129(5):697-713. PubMed ID: 36572991
[TBL] [Abstract][Full Text] [Related]
39. Pectasol-C Modified Citrus Pectin targets Galectin-3-induced STAT3 activation and synergize paclitaxel cytotoxic effect on ovarian cancer spheroids.
Hossein G; Halvaei S; Heidarian Y; Dehghani-Ghobadi Z; Hassani M; Hosseini H; Naderi N; Sheikh Hassani S
Cancer Med; 2019 Aug; 8(9):4315-4329. PubMed ID: 31197964
[TBL] [Abstract][Full Text] [Related]
40. LncRNA KB-1471A8.2 Overexpression Suppresses Cell Proliferation and Migration and Antagonizes the Paclitaxel Resistance of Ovarian Cancer Cells.
Zhang M; Liu S; Fu C; Wang X; Zhang M; Liu G; Dai C; Gong Z; Xu H; Fu Z; Xu P; Xu J; Jia X
Cancer Biother Radiopharm; 2019 Jun; 34(5):316-324. PubMed ID: 30892073
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
